Core Viewpoint - Plus Therapeutics, Inc. has received a delinquency notification from Nasdaq due to the delayed filing of its Quarterly Report for the period ended March 31, 2025, but this does not immediately affect its listing status on Nasdaq [1][2]. Group 1: Compliance and Filing Status - The Company must submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) by July 21, 2025 [2]. - If the compliance plan is accepted, Nasdaq may grant an extension of up to 180 calendar days, allowing the Company until November 17, 2025, to regain compliance [2]. - The Company is actively working to file the Quarterly Report as soon as possible and aims to return to a normal filing schedule for the remainder of 2025 [2]. Group 2: Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging cancers of the central nervous system [3]. - The Company employs a combination of image-guided local beta radiation and targeted drug delivery methods, with key programs targeting leptomeningeal metastases and recurrent glioblastoma [3]. - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [3].
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q